PET/MRI in Patients With Suspected Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

May 31, 2022

Study Completion Date

August 31, 2022

Conditions
Prostate Cancer
Interventions
DRUG

68Ga- PSMA-HBED-CC

Patients will receive a dual-tracer PET/MRI scan. FEC and 68Ga-PSMA-HBED-CC, for tissue metabolism and surface marker expressions, as specific PET-tracers as well as multiparametric MRI methods (T2w, DCE, DWI) are used.

DEVICE

Biograph mMR, Siemens

All PET-MRI examinations will be performed using a hybrid PET-MRI system (Biograph mMR, Siemens, Germany) capable of simultaneous data acquisition. The system consists of an MRI-compatible state-of the art PET detector integrated in a 3.0-T whole-body MRI scanner.

Trial Locations (1)

1090

Department of Biomedical Imaging and Image-guided Therapy, Vienna

Sponsors
All Listed Sponsors
collaborator

BSM Diagnostica GmbH Vienna

UNKNOWN

collaborator

Siemens Healthcare GmbH

UNKNOWN

lead

Medical University of Vienna

OTHER